Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment
- Registration Number
- NCT00935675
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Brief Summary
Evaluation of the effectiveness of escitalopram on depressive symptoms after 3 months in patients with head and neck squamous cell carcinomas (oral cavity, larynx, oropharynx and hypopharynx) and with an HADS total score \> 11
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Head and neck squamous cell carcinomas, stage I to IVb
- First-line curative cancer therapy : surgery and/or brachytherapy and/or chemotherapy
- HADS- T >11
- Aged 18 to 75 yo, written consent required
- OMS>2
Exclusion Criteria
- Palliative care
- Previous head and neck cancer
- Bipolar disorder or schizophrenia
- Severe major depressive disorder (DSM-IV TR)
- Expressed suicidal ideation
- Severe untreated organic disorder, especially acute infectious disorder
- ASAT/ALAT > 3N
- Clearance of creatinin < 30 ml/mn
- Hyponatremia
- Antecedent of delirium tremens or acute alcohol withdrawal disorder
- Antecedent of upper gastro-intestinal bleeding
- Antecedent of toxicity or inefficacy of a previous treatment with escitalopram
- Unauthorized treatments :- Antidepressant or antiepileptic (clonazepam authorized)- Hypnotic except zolpidem - Anxiolytic except clonazepam, clorazepate or diazepam- bupropion or varenicline
- Pregnancy or lactation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Escitalopram - Antidepressant treatment Escitalopram -
- Primary Outcome Measures
Name Time Method Evaluation of the effectiveness of escitalopram on depressive symptoms after 3 months 3 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Institut Gustave Roussy
🇫🇷Villejuif, France